StimCardio Secures $30 Million in Series A Funding for Wearable Atrial Fibrillation Therapy

StimCardio Medical has announced the completion of an oversubscribed $30m Series A funding round to advance its non-invasive wearable device, Rhyvive, designed for individuals with atrial fibrillation. The investment round was led by Metis Medtech, alongside Catalyst Health Ventures, several corporate strategic investors, and other new and existing backers.

Funding Allocation and Upcoming Clinical Evaluation

StimCardio plans to allocate the capital towards its upcoming multi-centre pivotal clinical trial, named NeuroPulse 2. Funds will also support preparations for a De Novo classification request to the US Food and Drug Administration (FDA).

The planned pivotal trial will assess whether delivering wearable neuromodulation alongside catheter ablation enhances clinical outcomes compared with catheter ablation by itself. StimCardio’s Rhyvive investigational device is a wrist-worn closed-loop therapeutic system combining physiological sensing with non-invasive median nerve stimulation. Designed as an adjunctive therapy following catheter ablation, the system targets autonomic nervous system pathways to lower recurrences of atrial arrhythmias such as atrial fibrillation within a home setting.

Previous Study Findings and Future Outlook

The funding round follows results from the NeuroPulse 1 pilot study, which appeared in Heart Rhythm and was presented as a late-breaking clinical trial at HRX Live 2026. The randomised, double-blind, sham-controlled investigation showed a statistically significant reduction in post-ablation recurrent atrial arrhythmia episodes among individuals receiving active median nerve stimulation compared with a sham control.

StimCardio Medical CEO Amir Soltanianzadeh stated that the company’s vision is to establish non-invasive neuromodulation as a new therapeutic category in cardiac electrophysiology. Lead investor Metis Medtech is an investment and advisory firm founded by CEO John Slump, who has previously completed four medical device exits, including Atraverse Medical and Farapulse in cardiac electrophysiology, totalling over $1.25bn in aggregate transaction value.

StimCardio intends to extend its wearable neuromodulation technology to additional cardiovascular and atrial fibrillation indications in the future.

• StimCardio Medical completed a $30m Series A funding round led by Metis Medtech.
• Capital will fund the upcoming NeuroPulse 2 multi-centre pivotal clinical trial and FDA De Novo submission preparations.
• The investigational Rhyvive wrist-worn device combines physiological sensing with non-invasive median nerve stimulation.